ProSensa Holding N.V. And Partners Awarded Second European Consortium FP7 Research Grant

Published: Nov 25, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Leiden, The Netherlands and Newcastle, UK, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, and Newcastle University, UK, have announced the award of a second Framework Programme 7 (FP7) research grant from the European Commission. This new FP7 research grant totals approximately EUR 6 million to support the development of imaging biomarkers for Duchenne muscular dystrophy (DMD).

Help employers find you! Check out all the jobs and post your resume.

Back to news